Research Article

Formulation and Evaluation of Transdermal Patch of Repaglinide

Shailesh T. Prajapati, Charmi G. Patel, and Chhagan N. Patel

Department of Pharmaceutics, Shri Sarvajanik Pharmacy College, Gujarat, Mehsana 384001, India

Correspondence should be addressed to Shailesh T. Prajapati, stprajapati@gmail.com

Received 15 April 2011; Accepted 17 May 2011

Academic Editors: M. Moneghini and J. Torrado

Copyright © 2011 Shailesh T. Prajapati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repaglinide has the half life of 1 hour, and bioavailability in the body is 56% due to first-pass metabolism. The total daily dose of Repaglinide is 16 mg (e.g., 4 mg four times daily depending on meal patterns); hence, it required frequent dosing. Transdermal patch of Repaglinide was prepared to sustain the release and improve bioavailability of drug and patient compliance. Different formulations were prepared by varying the grades of HPMC and concentration of PVP K30 by solvent casting method. The prepared formulations were evaluated for various parameters like thickness, tensile strength, folding endurance, % elongation, % moisture content, % moisture uptake, % drug content, in vitro drug release, in vitro permeation, and drug excipient compatibility. A 3² full factorial design was applied to check the effect of varying the grades of HPMC (X₁) and PVP concentration (X₂) on the responses, that is, tensile strength, percentage drug released in 1 hr (Q₁), 9 hr (Q₉), and diffusion coefficient as a dependent variables. In vitro release data were fitted to various models to ascertain kinetic of drug release. Regression analysis and analysis of variance were performed for dependent variables. The results of the F² statistics between factorial design batches and theoretical profile were used to select optimized batch. Batch F6 was considered optimum batch which contained HPMC K100 and PVP (1.5%), showed release 92.343% up to 12 hr, and was more similar to the theoretical predicted dissolution profile (f² = 69.187).

1. Introduction

Transdermal drug delivery system (TDDS) has been an increased interest in the drug administration via the skin for both local therapeutic effects on diseased skin (topical delivery) as well as for systemic delivery of drugs. The skin as a site of drug delivery has a number of significant advantages over many other routes of drug administration, including the ability to avoid problems of gastric irritation, pH and emptying rate effects, avoid hepatic first-pass metabolism thereby increasing the bioavailability of drug, reduce the risk of systemic side effects by minimizing plasma concentrations compared to oral therapy, provide a sustained release of drug at the site of application; rapid termination of therapy by removal of the device or formulation, the reduction of fluctuations in plasma levels of drugs, and avoid pain associated with injections. The transdermal delivery can also eliminate pulsed entry into the systemic circulation, which might often cause undesirable side effects [1].

Diabetes mellitus is a major and growing health problem worldwide and an important cause of prolonged ill health and early death. It is a chronic metabolic disorder characterized by a high blood glucose concentration (hyperglycemia) caused by insulin deficiency, and it is often combined with insulin resistance [2]. Repaglinide is an oral blood-glucose-lowering drug of the meglitinide class use to treat NIDDM (noninsulin-dependent diabetes mellitus). It lowers blood glucose by stimulating the release of insulin from the pancreas. It has an extremely short half life of 1 h. In addition, the oral bioavailability of Repaglinide is low (56%) due to extensive hepatic first-pass effect. Dosage frequency of Repaglinide is 0.5 to 4 mg in 3 to 4 times in a day. It has melting point of 130-131°C and mol. wt. 452.58 [3–6]. It belongs to class 2 drug. Repaglinide topical preparation may be beneficial to the patient since it reduce adverse effects and avoid the hepatic first-pass metabolism. The need for transdermal delivery of Repaglinide is further justified due to the requirement of maintaining unfluctuating plasma concentrations for effective management of blood sugar for long period in diabetic patients.

The purpose of the present work was to develop transdermal formulation of Repaglinide which increases the patient...
compliance and also sustain the release of drug to increase the bioavailability by using different grades of HPMC and PVP K30 as polymers.

2. Materials and Methods

2.1. Materials. Repaglinide was received as a gift sample from Torrent Pharmaceutical Ltd., Gujarat, India. HPMC K4M, HPMC K100, and HPMC E15 LV were purchased from Yarrow Chem, Mumbai, India. PVP K30 was obtained from SD fine—Chem. Ltd, Mumbai. Polyethylene glycol 400 and propylene glycol were obtained from Merck Specialities Private Ltd. (Mumbai) and Chemdyes Corporation (Ahmedabad, Gujarat) respectively. Cellulose acetate membrane was obtained from Sartorius Biotech GmbH (Germany). All other materials and chemicals used were of either pharmaceutical or analytical grade.

2.2. Methods

2.2.1. Preparation of Transdermal Patch. Drug-loaded matrix-type transdermal patches of Repaglinide were prepared by using solvent casting method. A petri dish with a total area of 44.15 cm² was used. Polymers were accurately weighed and dissolved in 10 mL of water, methanol (1:1) solution and kept aside to form clear solution. Drug was dissolved in the above solution and mixed until clear solution was obtained. Polyethylene glycol 400 (30% w/w of total polymer) was used as plasticizer and propylene glycol (15% w/w of total polymer) was used as permeation enhancer. The resulted uniform solution was cast on the petri dish, which was lubricated with glycerin and dried at room temperature for 24 h. An inverted funnel was placed over the petri dish to prevent fast evaporation of the solvent. After 24 h, the dried patches were taken out and stored in a desiccator for further studies.

2.2.2. Preliminary Screening. Preliminary study was carried out to check effect of various polymer combinations on transdermal patch formulation. Composition of preliminary trial batches P1 to P5 is shown in Table 1.

2.2.3. Optimization of Variables Using Full Factorial Design. A 3²-randomized full factorial design was used in the present study. In this design, 2 independent factors were evaluated, each at 3 levels, and experimental trials were performed for all 9 possible combinations. The different grades of HPMC (X₁) and concentration of PVP K30% (X₂) were chosen as independent variables in 3² full factorial designs. Tensile strength, cumulative % drug release at 1 h (Q₁), cumulative % drug release at 9 h (Q₉), and diffusion coefficient (n) were taken as dependent variables. The formulation layout for the factorial design batches (F1 to F9) are shown in Table 2.

2.2.4. Evaluation Parameters of Transdermal Patch.

Folding Endurance [8]. A strip of specific area (2 cm × 2 cm) was cut evenly and repeatedly folded at the same place till it broke. The number of times the film was folded at the same place without breaking gave the value of the folding endurance.

Tensile Strength [7]. The tensile strength of the patch was evaluated by using the tensiometer (Erection and instrumentation, Ahmedabad). It consists of two load cell grips. The lower one was fixed and upper one was movable. Film strips with dimensions of 2*2 cm were fixed between these cell grips, and force was gradually applied till the film broke. The tensile strength was taken directly from the dial reading in kg.

Percentage Elongation Break Test [9]. The percentage elongation break was determined by noting the length just before the break point, the percentage elongation was determined from the below mentioned formula:

\[
\text{Elongation percentage} = \left(\frac{L_1 - L_2}{L_2}\right) \times 100, \quad (1)
\]

where \(L_1\) is the final length of each strip, and \(L_2\) is the initial length of each strip.

Thickness [8]. Patch thickness was measured using digital micrometer screw gauge at three different places, and the mean value was calculated.

Drug Content [1]. A specified area of patch (2 cm × 2 cm) was dissolved in 100 mL methanol and shaken continuously for 24 h. Then the whole solution was ultrasonicated for 15 min. After filtration, the drug was estimated spectrophotometrically at wavelength of 281 nm and determined the drug content.

Percentage Moisture Content [8]. The prepared films were weighed individually and kept in a desiccator containing fused calcium chloride at room temperature for 24 h. After 24 h, the films were reweighed and determined the percentage moisture content from the below mentioned formula:

\[
\text{Percentage moisture content} = \left(\frac{\text{Initial weight} - \text{Final weight}}{\text{Final weight}}\right) \times 100. \quad (2)
\]

Percentage Moisture Uptake [8]. The weighed films were kept in a desiccators at room temperature for 24 h containing saturated solution of potassium chloride in order to maintain 84% RH. After 24 h, the films were reweighed and determine the percentage moisture uptake from the below mentioned formula:

\[
\text{Percentage moisture uptake} = \left(\frac{\text{Final weight} - \text{Initial weight}}{\text{Initial weight}}\right) \times 100. \quad (3)
\]

In Vitro Drug Release Studies [1]. In Vitro drug release studies were performed by using a Franz diffusion cell with
Table 1: Preliminary trial batches.

| Batch code | Polymer | Polymer proportion | Solvent | Plasticizer (30% w/w)* |
|------------|---------|--------------------|---------|------------------------|
| P1         | PVA : PVP | 1 : 1              | Water   | PG                     |
| P2         | HPMC K100M : PVP | 1 : 1          | Water   | PEG                    |
| P3         | HPMC K4M : PVP | 1 : 1              | Water   | PEG                    |
| P4         | EC : PVP | 1 : 4              | CHCl3   | PG                     |
| P5         | EC : HPMC K4M 3 : 7 | Ethanol : DCM | PEG     |                        |

Each batch contains 4 mg drug in 4 cm² area. * 30% w/w of total polymer weight.

Table 2: Formulation and evaluation of 3² full factorial design batches.

| Batch code | X1 (HPMC grade) | X2 (% PVP K30 concentration) | Y1 (tensile strength kg/cm²) | Y2 (Q₁)(%) | Y3 (Q₂)(%) | Y4 (diffusion coefficient) |
|------------|-----------------|-------------------------------|-----------------------------|------------|------------|-----------------------------|
| F1         | HPMC E15 LV     | 0.5                           | 0.38                        | 9.780612   | 88.91582   | 1.043                       |
| F2         | HPMC E15 LV     | 1                             | 0.46                        | 11.31122   | 90.59949   | 1.001                       |
| F3         | HPMC K100       | 1.5                           | 0.63                        | 12.22959   | 98.26531   | 0.983                       |
| F4         | HPMC K100       | 0.5                           | 0.45                        | 13.30102   | 54.54082   | 0.665                       |
| F5         | HPMC K100       | 1                             | 0.58                        | 13.91327   | 63.78827   | 0.746                       |
| F6         | HPMC K100       | 1.5                           | 0.92                        | 18.96429   | 75.90561   | 0.641                       |
| F7         | HPMC K4M        | 0.5                           | 0.53                        | 7.331633   | 48.52041   | 0.959                       |
| F8         | HPMC K4M        | 1                             | 0.84                        | 8.862245   | 37.98469   | 0.656                       |
| F9         | HPMC K4M        | 1.5                           | 0.95                        | 9.627551   | 57.70408   | 0.853                       |

In Vitro Permeation Study [10]. An in vitro permeation study was carried out by using Franz diffusion cell. Full thickness abdominal skin of male Wistar rat weighing 200 to 250 g was used. Hair from the abdominal region was removed carefully by using an electric clipper; the dermal side of the skin was thoroughly cleaned with distilled water to remove any adhering tissues or blood vessels, equilibrate for an hour in phosphate buffer pH 7.4 before starting the experiment, and was placed on a magnetic stirrer with a small magnetic needle for uniform distribution of the diffusant. The temperature of the cell was maintained at 32 ± 0.5°C using a thermostatically controlled heater. The isolated rat skin piece was mounted between the compartments of the diffusion cell, with the epidermis facing upward into the donor compartment. Sample volume of 5 mL was removed from the receptor compartment at regular intervals, and an equal volume of fresh medium was replaced. Samples were filtered through whatman filter and were analyzed using Shimadzu UV 1800 double-beam spectrophotometer (Shimadzu, Kyoto, Japan). Flux was determined directly as the slope of the curve between the steady-state values of the amount of drug permeated (mg/cm²) versus time in hours and permeability coefficient was deduced by dividing the flux by the initial drug load (mg/cm²).

2.2.5. Kinetic Modeling of Dissolution Data. The release profile of all batches were fitted to various mathematical models such as Zero order, First order, Higuchi [11], Hixon and Crowell [12], and Korsmeyer et al. [13], to ascertain the kinetic of drug release.

2.2.6. Comparison of Dissolution Profiles for Selection of Optimum Batch. The similarity factor (f₂) given by SUPAC guidelines for a modified release dosage form was used as a basis to compare release profiles. The release profiles are considered to be similar when f₂ is between 50 and 100. The release profile of products were compared using an f₂ which is calculated from following formula:

\[
f₂ = 50 \times \log \left( 1 + \frac{1}{n} \sum_{t=1}^{n} w_t (R_t - T_t)^2 \right)^{-0.5} \times 100,
\]

(4)
Table 3: Results for preliminary trial batches.

| Batch code | Thickness (mm) | Tensile strength (kg/cm²) | % elongation | Folding endurance | CPR (%) |
|------------|----------------|---------------------------|--------------|-------------------|---------|
| P1         | 0.12           | 20                        | 22.5         | 82                | 101.26  |
| P2         | 0.13           | 22                        | 22.5         | 79                | 90.03   |
| P3         | 0.15           | 20                        | 17.5         | 76                | 75.89   |
| P4         | 0.15           | 9                         | 5            | 22                | 65.27   |
| P5         | 0.20           | 8                         | 5            | 20                | 62.49   |

Table 4: Evaluation parameters of factorial batches F1 to F9.

| Sr. no. | Batch code | Folding endurance | Tensile strength (kg/cm²) (mean ± S.D.) | % Elongation (Mean ± S.D.) | Thickness (mm) (mean ± S.D.) | % Drug content (mean ± S.D.) | f2 value |
|---------|------------|--------------------|----------------------------------------|----------------------------|--------------------------------|-------------------------------|----------|
| 1       | F1         | < 150              | 0.38 ± 0.015                            | 41.2 ± 0.015               | 0.12 ± 0.025                  | 78.98                         | 52.58    |
| 2       | F2         | < 150              | 0.46 ± 0.012                            | 38.8 ± 0.014               | 0.15 ± 0.062                  | 78.941                        | 49.97    |
| 3       | F3         | > 200              | 0.63 ± 0.015                            | 37.1 ± 0.012               | 0.25 ± 0.022                  | 78.63                         | 45.44    |
| 4       | F4         | > 200              | 0.45 ± 0.014                            | 40.2 ± 0.013               | 0.22 ± 0.012                  | 77.851                        | 31.38    |
| 5       | F5         | > 200              | 0.58 ± 0.015                            | 39.6 ± 0.017               | 0.15 ± 0.015                  | 78.327                        | 44.75    |
| 6       | F6         | > 200              | 0.92 ± 0.017                            | 35.8 ± 0.012               | 0.17 ± 0.013                  | 77.956                        | 69.18    |
| 7       | F7         | > 200              | 0.53 ± 0.011                            | 39.2 ± 0.013               | 0.16 ± 0.021                  | 75.829                        | 26.13    |
| 8       | F8         | > 200              | 0.84 ± 0.017                            | 28.9 ± 0.015               | 0.13 ± 0.018                  | 74.683                        | 23.09    |
| 9       | F9         | > 200              | 0.95 ± 0.015                            | 30.1 ± 0.015               | 0.23 ± 0.015                  | 74.282                        | 34.03    |

Values expressed as mean ± S.D., n = 3.

where \( n \) is the release time and \( R_t \) and \( T_t \) are the reference (here this is the theoretical profile of Repaglinide and test value at time \( t \) [14].

2.2.7. Drug Excipients Compatibility Study. Fourier transform infrared (FTIR) technique was used to study the physical and chemical interaction between drug and excipients. FTIR spectrum of Repaglinide, HPMC K4M, HPMC K100, HPMC E15 LV, PVP K30, and a physical mixture of Repaglinide: HPMC (K100/K4M/E15 LV): PVP K30 was recorded using KBr mixing method on FTIR (FTIR-1700, Shimadzu, Kyoto, Japan). IR spectra are shown in Figures 7 and 8.

3. Result and Discussion

3.1. Preliminary Study. All the batches of transdermal patch showed thickness variation range from 0.12 to 0.20 mm as shown in Table 3. High thickness of batch P4 and P5 was found, it may be due to low solubility of ethyl cellulose in solvent render uneven distribution of polymer layer. All the batches of transdermal patch showed tensile strength and % elongation in uniform range from 16 to 22 and 17.5 to 22.5, respectively, except batches P4 and P5 may be due to poor solubility of ethyl cellulose and weak bond formation (Table 3). Hence batches P4 and P5 were eliminated for further study. Batch P1 containing PVA: PVP shows fast release of drug (101.26% at 8 h) from patch due to burst effect of PVP and also more solubility in water. So batch P1 was also eliminated.

3.2. Folding Endurance, Tensile Strength, % Elongation and Thickness. The results of folding endurance, tensile strength, % elongation and thickness of factorial design batches are shown in Table 4. The folding endurance values of all the factorial design patches were found satisfactory which indicates that the patches prepared using PEG 400 in a concentration of 30% w/w of polymer were having optimum flexibility and were not brittle. The tensile strength of the patches prepared with HPMC E15 and PVP were found in between 0.12 kg/cm² to 0.20 kg/cm² for the patches composed of HPMC K100 and were 0.15% to 41.2% ± 0.015%. The formulation F8 showed minimum % elongation among the other entire factorial design batches 28.95 ± 0.015%. It indicates inverse relation between tensile strength and % elongation. The thickness ranges were 0.12 ± 0.025 to 0.25 ± 0.022 mm. The results showed that the patches were uniform, as it was evidenced by SD value, which were less than 0.01 for all the factorial design batches.

3.3. Moisture Content, Moisture Uptake, and Drug Content Studies. The moisture content in the patches ranged from 3.24 ± 0.017 to 4.12 ± 0.015%. The moisture content in the formulations was found to be increased by increase in
the concentration of PVP K30 and also with increasing the grade of HPMC. The moisture uptake in the patches ranged from $5.27 \pm 0.012$ to $7.89 \pm 0.019\%$. The moisture uptake was found to be higher in batches F7, F8, and F9, which might be due to HPMC K4M. The lower moisture content in the formulations helps them to remain stable and become a completely dried and brittle film. Again, low moisture uptake protects the material from microbial contamination and bulkiness. The drug content ranged from 74.282 to 78.98\%. All formulations were acceptable with regard to Repaglinide content (Table 4).

### 3.4. In Vitro Drug Release Study

The drug release characteristics of the formulation were studied in in vitro conditions by using artificial semipermeable membrane. The formulation F1–F3 has shown release of about 96.83\%, 101.057\% at 10 h and 98.26\% at 9 h, respectively. This is may be due to low viscosity of HPMC E15 LV polymer which is rapidly soluble than HPMC K4M and HPMC K100. The formulation F4–F9 has shown release of about 70.02\%, 88.49\%, 92.343\%, 68.01\%, 69.014\%, and 84.804\% at 12th hour, respectively (Figure 1). HPMC K4M shows slow release mechanism was non-Fickian diffusion (Table 2) [15].

![In vitro drug release profile](image1)

**Figure 1:** In vitro drug release profile for batch F1 to F9.

According to Korsmeyer-Peppas model, a value of slope for drug release was found to be F2>F3>F1>F6>F5>F9>F4>F8>F7. The in vitro release data of F1 to F7 formulations fitted well into the Zero order equation, correlation coefficient values were between 0.9869 and 0.9986 while F8 and F9 follows first-order release. Hixon crowell law and Highuchi model was applied to test the release mechanism follows zero order while for F4, F5, F6, and F8 was between 0.5 to 0.85 which indicates the release mechanism was non-Fickian diffusion (Table 2).

### 3.5. In Vitro Permeation Study

The formulation F6 exhibited 87.4\% of drug permeated in 12 h with a flux of 8.65 $\mu g/cm^2/h$ (with a permeation coefficient of 3.967 cm/h) (Figure 2). Plotting the cumulative amounts of drug permeated per square centimeter of the patches through the rat abdominal skin against time showed that the permeation profiles of drug might follow zero-order kinetics as it was evident by correlation coefficients 0.992, better fit than first order ($R^2 = 0.982$) and Higuchi model ($R^2 = 0.987$) (Figure 3).

![In vitro drug permeation profile for optimum batch F6](image2)

**Figure 2:** In vitro drug permeation profile for batch F6.

According to korsmeyer–Peppas model, a value of slope for F6 was between 0.5 and 0.85 (0.678) which indicates that the release mechanism was non-Fickian diffusion. The results of drug permeation from transdermal patches of Repaglinide through the rat abdominal skin confirmed that Repaglinide was released from the formulation and permeated through the rat skin and, hence, could possibly permeate through the human skin.

![Response surface plot for tensile strength](image3)

**Figure 3:** Response surface plot for tensile strength.

### 3.6. Full Factorial Design

A statistical model incorporating interactive and poly nominal terms was used to evaluate the responses.

$$Y_i = b_0 + b_1 X_1 + b_2 X_2 + b_3 X_1 X_2 + b_4 X_1^2 + b_5 X_2^2,$$

where $Y$ is the dependent variable, $b_0$ is the arithmetic mean response of the 9 runs, and $b_i$ is the estimated coefficient for the factor $Xi$. The main effects ($X_1$ and $X_2$)
represent the average result of changing 1 factor at a time from its low to high values. The two way interaction terms \( (X_{12}) \) show how the response changes when two factors are simultaneously changed. Polynomial terms \( (X_{11} \text{ and } X_{22}) \) are included to investigate nonlinearity. The in vitro release profile for 9 batches showed a variation (i.e., tensile strength, \( Q_1 \), \% cumulative drug release at 1 h \( Q_9 \), and diffusion coefficient). The data indicate that the release profile of the drug is strongly dependent on the selected independent variables. The fitted equations (full and reduced) relating the responses, tensile strength, \( Q_1 \), \( Q_9 \), and diffusion coefficient to the transformed factor are shown in Table 5. The polynomial equations can be used to draw conclusions after considering the magnitude of coefficient and the mathematical sign it carries (i.e., negative or positive). Table 6 shows the results of analysis of variance (ANOVA), which was performed to identify insignificant factors. Data were analyzed using Microsoft Excel.

\( R^2 \) value for tensile strength, \( Q_1 \), \( Q_9 \), and diffusion coefficient are 0.9431, 0.9318, 0.9648, and 0.8030, respectively, indicating good correlation between dependent and independent variables. The reduced models were developed for response variables by omitting the insignificant terms with \( P > 0.05 \). The terms with \( P < 0.05 \) were considered statistically significance and retained in the reduced model. The coefficients for full and reduced models for response variables are shown in Table 5.

3.7. Full and Reduced Model for Tensile Strength. The significance levels of the coefficients \( b_{12}, b_1^1, \text{ and } b_2^2 \) were found to be \( P = 0.3833, 0.7763, \text{ and } 0.7959 \), respectively; hence, they were omitted from the full model to generate a reduced model. The results of statistical analysis are shown in Table 5. The coefficients \( b_1 \) and \( b_2 \) were found to be significant at \( P < 0.05 \); hence, they were retained in the reduced model. The reduced model was tested in proportion to determine whether the coefficients \( b_{12}, b_1^1, \text{ and } b_2^2 \) contribute significant information to the prediction of tensile strength. The results of model testing are shown in Table 6. The critical value of \( F \) for \( \alpha = 0.05 \) is equal to 9.27 (df = 3, 3). Since the calculated value \( (F = 0.404) \) is less than critical value \( (F = 9.27) \), it may be concluded that the terms \( b_{12}, b_1^1, \text{ and } b_2^2 \) do not contribute significantly to the prediction of tensile strength and can be omitted from the full model to generate the reduced model.

3.8. Full and Reduced Model for \( Q_1 \). The significance levels of the coefficients \( b_1, b_2, b_{12} \text{ and } b_2^2 \) were found to be \( P = 0.129, 0.064, 0.962, \text{ and } 0.658 \), respectively, so they were omitted from the full model to generate a reduced model. The results of statistical analysis are shown in Table 5. The coefficient
Table 5: Summary of results of regression analysis.

| Response (tensile strength) | $b_0$  | $b_1$  | $b_2$  | $b_{12}$ | $b_1^2$ | $b_2^2$ |
|-----------------------------|--------|--------|--------|----------|---------|---------|
| FM                          | 0.638889 | 0.141667 | 0.19  | 0.0425   | -0.01833 | 0.016667 |
| RM                          | 0.637778 | 0.141667 | 0.19  | -        | -        | -        |

| Response (Q1) | $b_0$  | $b_1$  | $b_2$  | $b_{12}$ | $b_1^2$ | $b_2^2$ |
|----------------|--------|--------|--------|----------|---------|---------|
| FM             | 15.05272 | -1.25 | 1.734694 | -0.038   | -5.53572 | 0.510204 |
| RM             | 15.39286 | -      | -      | -        | -5.53572 | -        |

| Response (Q9) | $b_0$  | $b_1$  | $b_2$  | $b_{12}$ | $b_1^2$ | $b_2^2$ |
|----------------|--------|--------|--------|----------|---------|---------|
| FM             | 60.39966 | -22.2619 | 6.649658 | -0.041   | 5.586733 | 6.517858 |
| RM             | 68.46939 | -22.2619 | -      | -        | -        | -        |

| Response (diffusion coefficient) | $b_0$  | $b_1$  | $b_2$  | $b_{12}$ | $b_1^2$ | $b_2^2$ |
|----------------------------------|--------|--------|--------|----------|---------|---------|
| FM                               | 0.64641 | -0.09322 | -0.03172 | -0.011   | 0.231885 | 0.056385 |
| RM                               | -      | -      | -      | -        | -        | -        |

FM: full model, RM: reduced model.

Table 6: Calculation for testing the model in portions.

| Regression | DF | SS    | MS     | $F$    | $R^2$   |
|------------|----|-------|--------|--------|---------|
| Tensile strength |     |       |        |        |          |
| FM          | 5  | 0.345469 | 0.069094 | 9.924378 | 0.94299 |
| RM          | 2  | 0.337017 | 0.168508 | 34.46109 | 0.91992 |
| Error       |    | 0.020886 | 0.006962 | -       | -       |

For Q1

| Regression | DF | SS    | MS     | $F$    | $R^2$   |
|------------|----|-------|--------|--------|---------|
| FM          | 5  | 89.24479 | 17.84896 | 8.196259 | 0.93179 |
| RM          | 1  | 61.28835 | 61.28835 | 38.43909 | 0.6399  |
| Error       |    | 6.533088 | 2.177696 | -       | -       |

For Q9

| Regression | DF | SS    | MS     | $F$    | $R^2$   |
|------------|----|-------|--------|--------|---------|
| FM          | 5  | 3386.258 | 677.2515 | 16.42181 | 0.964751 |
| RM          | 1  | 2973.555 | 2973.555 | 38.80292 | 0.847171 |
| Error       |    | 123.723  | 41.24098 | -       | -       |

| Regression | DF | SS    | MS     | $F$    | $R^2$   |
|------------|----|-------|--------|--------|---------|
| FM          | 5  | 0.172597 | 0.034519 | 2.445924 | 0.80302 |
| RM          | -  | -      | -      | -       | -       |
| Error       |    | 0.042339 | 0.014113 | -       | -       |

DF: degree of freedom; SS: sum of squares; MS: mean of squares; $R^2$: regression coefficient; FM: full model; RM: reduced model.
was found to be significant at $P < 0.05$; hence, it was retained in the reduced model. The reduced model was tested in proportion to determine whether the coefficient $b_1$, $b_2$, $b_{12}$, and $b_2^2$ contribute significance information to the prediction of $Q_1$. The results of model testing are shown in Table 6. The critical value of $F$ for $\alpha = 0.05$ is equal to 9.11 ($df = 4, 3$). Since the calculated value ($F = 3.209$) is less than critical value ($F = 9.11$), it may be concluded that the term $b_1$, $b_2$, $b_{12}$, and $b_2^2$ do not contribute significantly to the prediction of $Q_t$ and can be omitted from the full model to generate the reduced model.

3.9. Full and Reduced Model for $Q_9$. The significance levels of the coefficients $b_2$, $b_{12}$, $b_1$, and $b_2^2$ were found to be $P = 0.0849, 0.9905, 0.3062$, and 0.2466, respectively, so they were omitted from the full model to generate a reduced model. The results of statistical analysis are shown in Table 5. The coefficient $b_1$ was found to be significant at $P < 0.05$; hence, it was retained in the reduced model. The reduced model was tested in proportion to determine whether the coefficient $b_2$, $b_{12}$, $b_1$, and $b_2^2$ contribute significance information to the prediction of $Q_9$. The results of model testing are shown in Table 6. The critical value of $F$ for $\alpha = 0.05$ is equal to 9.11.


3.10. Full and Reduced Model for Diffusion Coefficient. The results of statistical analysis are shown in Table 5. None of the coefficients were found to be significant at $P < 0.05$; hence, reduced model was not obtained. So diffusion coefficient gives no significance effect. The results of model testing are shown in Table 6. The critical value of $F$ for $\alpha = 0.05$ is equal to 9.11 ($df = 4,3$). Since the calculated value ($F = 3.09$) is less than critical value ($F = 9.11$), it may be concluded that all the terms do not contribute significantly to the prediction of diffusion coefficient.

To demonstrate graphically the effect of grade of HPMC and concentration of PVP K30, the response surface plots generated were using Design expert 8.0.2 trial version software for the dependent variables tensile strength, $Q_1$, $Q_9$ (% drug release after 1, and 9 hours, resp.), and diffusion coefficient ($n$) shown in Figures 3–6, respectively.

3.11. Comparison of In Vitro Release Profile for Selection of Optimum Batch. Dissolution profiles of all batches of factorial design were compared with theoretical dissolution profile. The values of similarity factor ($f_2$) for batches F1 to F9 are shown in Table 4. Batch F6 showed highest $f_2$ value (69.187) among all the batches. Hence, batch F6 is more similar compared to other batches so it was selected as an optimum batch.

3.12. Drug Excipients Compatibility Study. Drug-excipients interactions play a vital role in the release of drug from formulation. The pure Repaglinide and its mixture with different grade of HPMC and PVP K30 were mixed separately with IR grade KBr and were scanned over a range of 400–4500 cm$^{-1}$ using FTIR instrument (FTIR-1700, Shimadzu, Kyoto, Japan). The drug exhibits peaks due to ketonic group, alcohol group, secondary amine, terminal CH$_3$ group, and C=O stretching in COOH and CONH. It was observed that main peaks of Repaglinide were present in mixture of drug and polymer, and no change in main peaks of the drug IR spectra in a mixture of drug and polymers was found. The FTIR study revealed no physical or chemical interactions of Repaglinide with each grade of HPMC and PVP K30 as evident from Figures 7 and 8.

4. Conclusion

The prepared transdermal drug delivery system of Repaglinide using different grades of HPMC and PVP K30 had shown good promising results for all the evaluated parameters. It was concluded that HPMC K100 and PVP K30 of moderate level useful for preparation of sustained release matrix transdermal patch formulation.

Acknowledgments

The authors thank Torrent Pharmaceutical Ltd. for providing gift sample for Repaglinide, and also thank Shri Sarvajanik Pharmacy College, Mehsana for providing all other ingredients and required infrastructure for the conduct of this research work.

References

[1] K. C. Garala, A. J. Shinde, and P. H. Shah, “Formulation and in-vitro characterization of monolithic matrix transdermal systems using HPMC/Eudragit S 100 polymer blends,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 1, no. 1, pp. 108–120, 2009.
[2] K. Ghosal, R. Rajan, and A. Nanda, “Effects of chemical enhancers on the release of glipizide through matrix patch,” International Journal of ChemTech Research, vol. 1, no. 4, pp. 1128–1130, 2009.
[3] “RxList. The Internet Index-prandin,” http://www.RxList.com/cgi/generic/prandin.htm.
[4] “Repaglinide from wikipedia, the free encyclopedia,” http://en.wikipedia.org/wiki/Repaglinide.
[5] http://www.drugbank.ca/drugs/DB00912.
[6] “Druglib.com, Theinformationportal,” http://www.druglib.com/activeingredient/repaglinide/prandin_cp.htm#c.
[7] A. Shivaraj, R. Panner Selvam, T. Tamiz Mani, and T. Sivakumar, “Design and evaluation of transdermal drug delivery of ketotifen fumarate,” International Journal of Pharmaceutical and Biomedical Research, vol. 1, no. 2, pp. 42–47, 2010.
[8] E. Keleb, R. Sharma, E. B. Mosa, and A. Z. Zaljahwi, “Transdermal drug delivery system- design and evaluation,” International Journal of Advances in Pharmaceutical Sciences, vol. 1, pp. 201–211, 2010.
[9] S. T. Lec, S. H. Yac, S. W. Kim, and B. Berner, “One way membrane for transdermal drug delivery system. II. System optimization,” International Journal of Pharmaceutics, vol. 77, no. 2-3, pp. 231–237, 1991.
[10] J. Singh, K. T. Tripathi, and T. R. Sakia, “Effect of penetration enhancers on the in vitro transport of ephedrine through rate skin and human epidermis from matrix based transdermal formulations,” Drug Development and Industrial Pharmacy, vol. 19, pp. 1623–1628, 1993.
[11] T. Higuchi, “Mechanism of sustained action mediation, theoretical analysis of rate of release of solid drugs dispersed in solid matrices,” Journal of Pharmaceutical Sciences, vol. 52, pp. 1145–1149, 1963.
[12] A. W. Hixon and J. H. Crowell, “Dependence of reaction velocity upon surface and agitation,” Industrial and Engineering Chemistry, vol. 23, pp. 923–931, 1931.
[13] R. W. Korsmeyer, R. Gurny, and E. Doelker, “Mechanisms of solute release from porous hydrophilic polymers,” International Journal of Pharmaceutics, vol. 15, no. 1, pp. 25–35, 1983.
[14] P. Coasta, J. Manuel, and S. Labao, “Modelling and comparison of dissolution profiles,” The European Journal of Pharmaceutical Sciences, vol. 13, pp. 123–133, 2002.
[15] J. Siepmann and N. A. Peppas, “Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose,” Advanced Drug Delivery Reviews, vol. 48, no. 2-3, pp. 139–157, 2001.